Flexion Therapeutics announces results of OA pain injection in cohort with type 2 diabetes

Flexion Therapeutics Inc. announced results from a clinical trial that indicated its osteoarthritis intra-articular injection was linked with a statistically significant and clinically relevant reduction in blood glucose levels among adults with type 2 diabetes and knee osteoarthritis compared with immediate-release triamcinolone acetonide injection.

According to a company press release, the double-blind, randomized, parallel group included 33 patients with type 2 diabetes and knee osteoarthritis (OA). Investigators compared the effect of Zilretta (FX006, Flexion Therapeutics Inc.) and immediate-release triamcinolone acetonide injection on blood glucose levels.

“We believe these data demonstrate that Zilretta may limit effects on blood glucose which, if approved, could have future implications for the many knee OA patients in the [United States] U.S. who also have type 2 diabetes. We look forward to including these topline data in the Zilretta new drug application which we plan to submit by the end of the year,” Michael Clayman, MD, the president and chief executive officer of Flexion Therapeutics, said in the release. In a previous phase 3 pivotal trial performed in knee OA patients, FX006 demonstrated clinical improvements for outcomes measuring pain, stiffness and function.

Reference: